Correction to: Candesartan treatment enhances liposome penetration and anti-tumor effect via depletion of tumor stroma and normalization of tumor vessel

Xin-jun Cai¹ · Zeng Wang² · Ying-ying Xu¹ · Gao-yi Yang³ · Ruo-ying Zhang¹ · Yu Wang¹

Published online: 26 August 2020
© Controlled Release Society 2020

Correction to: Drug Delivery and Translational Research <https://doi.org/10.1007/s13346-020-00842-0>

In the original article there is an error in part **a** in the caption of Fig. 6. Following is the complete corrected caption:
Fig. 6 Effect of different treatment groups dosing regimens on the percentage of CEPCs in PBMCs. **a** The representative photographs of flow cytometry analysis for the determination of the percentage of CD45⁺ CD146⁺ cells in PBMCs. A1: Control group. A2: Candesartan group (10 mg/kg). A3: Candesartan group (20 mg/kg). **b** The percentage of CEPCs in PBMCs after various treatment. Results were expressed as mean $\pm$ standard deviation (SD) ($n = 5$). Statistical comparisons were carried out by using one-way ANOVA. Compared with control group: ♦ $p < 0.05$; ♦♦ $p < 0.01$; ♦♦♦ $p < 0.001$

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1007/s13346-020-00842-0>

✉ Xin-jun Cai
zjtcxj@zcmu.edu.cn

- ¹ Department of Pharmacy, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou Red Cross Hospital, Hangzhou 310003, Zhejiang, People's Republic of China
- ² Department of Pharmacy, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou 310022, China
- ³ Department of Ultrasound, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou Red Cross Hospital, Hangzhou 310003, Zhejiang, People's Republic of China